A New Drug Helps Increase Survival Rates of Non-small Cell Lung Cancer Patients
A recent study performed by AstraZeneca and MedImmue reveals, provisionally, that a Phase III trial with the drug Imfinzi, also known as durvalumab, gives longer life to patients with advanced, inoperable, non-small cell lung cancer (NSCLC). The trial, known as PACIFIC Phase 3, tests Imfinzi in comparison to placebo drugs in patients […]
Continue readingEuropean Committee Approves Opdivo Advance
Opdivo Advances in Europe In response to the decision made in the United States last March, manufacturer Bristol-Myers Squibb has announced a new dosing schedule for Opdivo (nivolumab), recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency. This new dosing schedule lets physicians choose to prescribe Opdivo as a […]
Continue readingCHIPSA Looks Into Cuban Lung Cancer Vaccine United States Is Studying
New York Governor Andrew Cuomo (D) embarked on a historic trade mission in April and came back with something that could save thousands of lives: a lung cancer vaccine developed in Cuba. CimaVax, a vaccine for treating lung cancer, is coming to the United States for clinical trials. The vaccine was thoroughly studied for a quarter […]
Continue reading